Global and India Cephalosporin Market

Cephalosporin Comprehensive Study by Type (Branded, Generics), Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection, Others), Generation (First-generation Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, Fifth-generation Cephalosporin), Route of Drug Administration (Injection, Oral) Players and Region - Global Market Outlook to 2026

Cephalosporin Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 2.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Cephalosporin Market Scope
Cephalosporin is a bactericidal, broad-spectrum, β-lactam antibiotic originally derived from the fungus Acremonium. It is used to treat an extensive variety of bacterial infections, such as skin infections, respiratory tract infections, and urinary tract infections, among others. Cephalosporins are administered through oral and injections. Based on the type, the market has been segmented into branded and generics. The Rising Incidences of Pneumonia, Tonsillitis, Bronchitis, and Gonorrhea is the primary key factor driving the growth of the market.

According to AMA, the Global Cephalosporin market is expected to see growth rate of 2.1%

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Cephalosporin market throughout the predicted period.

Allergan Plc. (Ireland), Bristol-Myers Squibb Company (United States), F.Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline Plc. (United Kingdom), Lupin Limited (Lupin Pharmaceuticals, Inc.) (India), Merck & Co. Inc. (United States), Novartis International AG (Switzerland), Pfizer Inc. (United States), Sanofi (France) and Teva Pharmaceutical Industries Ltd (Israel) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Eli Lilly and Company (United States), Bayer HealthCare (Germany), Sun Pharmaceutical (India) and Shionog (Japan).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Cephalosporin market by Type (Branded and Generics), by Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection and Others) and Region with country level break-up.

On the basis of geography, the market of Cephalosporin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 18 March 2019, Allergan plc. has announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam), expanding the label to include pediatric patients 3 months and older for the treatment of complicated intra-abdominal infections (cIAI) in combination with metronidazole and complicated urinary tract infections (cUTI).


Market Trend
  • Increased Use of Third-Generation Cephalosporin Antibiotics

Market Drivers
  • The Rising Incidences of Pneumonia, Tonsillitis, Bronchitis, and Gonorrhea
  • Increase in R&D Activities to Develop Highly Efficient & Safe Drugs
  • The upsurge in Use of Combination Therapies
  • The rise in Funding For the Development of Antibiotics

Opportunities
  • Discovery of Advanced Prospect Molecules
  • Introduction of Novel Combination Therapies to Treat Antibiotic-Resistant Microbial Infections

Restraints
  • Side Effects Associated With Cephalosporin
  • Uncertain Regulatory Reforms
  • Antibiotic Resistance to Cephalosporin, And fewer Drugs in Pipeline


Key Target Audience
Cephalosporin Drugs & Injections Manufacturers, Cephalosporin Drugs & Injections Traders/Distributors/Wholesalers, Cephalosporin Drugs & Injections Importer/Exporter, Regulatory & Government Bodies, Research & Consulting Firms, Downstream Vendors and Others

Report Objectives / Segmentation Covered

By Type
  • Branded
  • Generics
By Application
  • Respiratory Tract Infection
  • Skin Infection
  • Ear Infection
  • Urinary Tract Infection
  • Sexually Transmitted Infection
  • Others
By Generation
  • First-generation Cephalosporin
  • Second-generation Cephalosporin
  • Third-generation Cephalosporin
  • Fourth-generation Cephalosporin
  • Fifth-generation Cephalosporin

By Route of Drug Administration
  • Injection
  • Oral

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Incidences of Pneumonia, Tonsillitis, Bronchitis, and Gonorrhea
      • 3.2.2. Increase in R&D Activities to Develop Highly Efficient & Safe Drugs
      • 3.2.3. The upsurge in Use of Combination Therapies
      • 3.2.4. The rise in Funding For the Development of Antibiotics
    • 3.3. Market Trends
      • 3.3.1. Increased Use of Third-Generation Cephalosporin Antibiotics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global Cephalosporin, by Type, Application, Generation, Route of Drug Administration and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cephalosporin (Value)
      • 5.2.1. Global Cephalosporin by: Type (Value)
        • 5.2.1.1. Branded
        • 5.2.1.2. Generics
      • 5.2.2. Global Cephalosporin by: Application (Value)
        • 5.2.2.1. Respiratory Tract Infection
        • 5.2.2.2. Skin Infection
        • 5.2.2.3. Ear Infection
        • 5.2.2.4. Urinary Tract Infection
        • 5.2.2.5. Sexually Transmitted Infection
        • 5.2.2.6. Others
      • 5.2.3. Global Cephalosporin by: Generation (Value)
        • 5.2.3.1. First-generation Cephalosporin
        • 5.2.3.2. Second-generation Cephalosporin
        • 5.2.3.3. Third-generation Cephalosporin
        • 5.2.3.4. Fourth-generation Cephalosporin
        • 5.2.3.5. Fifth-generation Cephalosporin
      • 5.2.4. Global Cephalosporin by: Route of Drug Administration (Value)
        • 5.2.4.1. Injection
        • 5.2.4.2. Oral
      • 5.2.5. Global Cephalosporin Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Cephalosporin: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. Allergan Plc. (Ireland)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Bristol-Myers Squibb Company (United States)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. F.Hoffmann-La Roche Ltd. (Switzerland)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. GlaxoSmithKline Plc. (United Kingdom)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. Lupin Limited (Lupin Pharmaceuticals, Inc.) (India)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. Merck & Co. Inc. (United States)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. Novartis International AG (Switzerland)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. Pfizer Inc. (United States)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
      • 6.1.9. Sanofi (France)
        • 6.1.9.1. Business Overview
        • 6.1.9.2. Products/Services Offerings
        • 6.1.9.3. Financial Analysis
        • 6.1.9.4. SWOT Analysis
      • 6.1.10. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.1.10.1. Business Overview
        • 6.1.10.2. Products/Services Offerings
        • 6.1.10.3. Financial Analysis
        • 6.1.10.4. SWOT Analysis
  • 7. Global Cephalosporin Sale, by Type, Application, Generation, Route of Drug Administration and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cephalosporin (Value)
      • 7.2.1. Global Cephalosporin by: Type (Value)
        • 7.2.1.1. Branded
        • 7.2.1.2. Generics
      • 7.2.2. Global Cephalosporin by: Application (Value)
        • 7.2.2.1. Respiratory Tract Infection
        • 7.2.2.2. Skin Infection
        • 7.2.2.3. Ear Infection
        • 7.2.2.4. Urinary Tract Infection
        • 7.2.2.5. Sexually Transmitted Infection
        • 7.2.2.6. Others
      • 7.2.3. Global Cephalosporin by: Generation (Value)
        • 7.2.3.1. First-generation Cephalosporin
        • 7.2.3.2. Second-generation Cephalosporin
        • 7.2.3.3. Third-generation Cephalosporin
        • 7.2.3.4. Fourth-generation Cephalosporin
        • 7.2.3.5. Fifth-generation Cephalosporin
      • 7.2.4. Global Cephalosporin by: Route of Drug Administration (Value)
        • 7.2.4.1. Injection
        • 7.2.4.2. Oral
      • 7.2.5. Global Cephalosporin Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cephalosporin: by Type(USD Million)
  • Table 2. Cephalosporin Branded , by Region USD Million (2015-2020)
  • Table 3. Cephalosporin Generics , by Region USD Million (2015-2020)
  • Table 4. Cephalosporin: by Application(USD Million)
  • Table 5. Cephalosporin Respiratory Tract Infection , by Region USD Million (2015-2020)
  • Table 6. Cephalosporin Skin Infection , by Region USD Million (2015-2020)
  • Table 7. Cephalosporin Ear Infection , by Region USD Million (2015-2020)
  • Table 8. Cephalosporin Urinary Tract Infection , by Region USD Million (2015-2020)
  • Table 9. Cephalosporin Sexually Transmitted Infection , by Region USD Million (2015-2020)
  • Table 10. Cephalosporin Others , by Region USD Million (2015-2020)
  • Table 11. Cephalosporin: by Generation(USD Million)
  • Table 12. Cephalosporin First-generation Cephalosporin , by Region USD Million (2015-2020)
  • Table 13. Cephalosporin Second-generation Cephalosporin , by Region USD Million (2015-2020)
  • Table 14. Cephalosporin Third-generation Cephalosporin , by Region USD Million (2015-2020)
  • Table 15. Cephalosporin Fourth-generation Cephalosporin , by Region USD Million (2015-2020)
  • Table 16. Cephalosporin Fifth-generation Cephalosporin , by Region USD Million (2015-2020)
  • Table 17. Cephalosporin: by Route of Drug Administration(USD Million)
  • Table 18. Cephalosporin Injection , by Region USD Million (2015-2020)
  • Table 19. Cephalosporin Oral , by Region USD Million (2015-2020)
  • Table 20. South America Cephalosporin, by Country USD Million (2015-2020)
  • Table 21. South America Cephalosporin, by Type USD Million (2015-2020)
  • Table 22. South America Cephalosporin, by Application USD Million (2015-2020)
  • Table 23. South America Cephalosporin, by Generation USD Million (2015-2020)
  • Table 24. South America Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 25. Brazil Cephalosporin, by Type USD Million (2015-2020)
  • Table 26. Brazil Cephalosporin, by Application USD Million (2015-2020)
  • Table 27. Brazil Cephalosporin, by Generation USD Million (2015-2020)
  • Table 28. Brazil Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 29. Argentina Cephalosporin, by Type USD Million (2015-2020)
  • Table 30. Argentina Cephalosporin, by Application USD Million (2015-2020)
  • Table 31. Argentina Cephalosporin, by Generation USD Million (2015-2020)
  • Table 32. Argentina Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 33. Rest of South America Cephalosporin, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Cephalosporin, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Cephalosporin, by Generation USD Million (2015-2020)
  • Table 36. Rest of South America Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 37. Asia Pacific Cephalosporin, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Cephalosporin, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Cephalosporin, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Cephalosporin, by Generation USD Million (2015-2020)
  • Table 41. Asia Pacific Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 42. China Cephalosporin, by Type USD Million (2015-2020)
  • Table 43. China Cephalosporin, by Application USD Million (2015-2020)
  • Table 44. China Cephalosporin, by Generation USD Million (2015-2020)
  • Table 45. China Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 46. Japan Cephalosporin, by Type USD Million (2015-2020)
  • Table 47. Japan Cephalosporin, by Application USD Million (2015-2020)
  • Table 48. Japan Cephalosporin, by Generation USD Million (2015-2020)
  • Table 49. Japan Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 50. India Cephalosporin, by Type USD Million (2015-2020)
  • Table 51. India Cephalosporin, by Application USD Million (2015-2020)
  • Table 52. India Cephalosporin, by Generation USD Million (2015-2020)
  • Table 53. India Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 54. South Korea Cephalosporin, by Type USD Million (2015-2020)
  • Table 55. South Korea Cephalosporin, by Application USD Million (2015-2020)
  • Table 56. South Korea Cephalosporin, by Generation USD Million (2015-2020)
  • Table 57. South Korea Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 58. Taiwan Cephalosporin, by Type USD Million (2015-2020)
  • Table 59. Taiwan Cephalosporin, by Application USD Million (2015-2020)
  • Table 60. Taiwan Cephalosporin, by Generation USD Million (2015-2020)
  • Table 61. Taiwan Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 62. Australia Cephalosporin, by Type USD Million (2015-2020)
  • Table 63. Australia Cephalosporin, by Application USD Million (2015-2020)
  • Table 64. Australia Cephalosporin, by Generation USD Million (2015-2020)
  • Table 65. Australia Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Cephalosporin, by Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Cephalosporin, by Application USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Cephalosporin, by Generation USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 70. Europe Cephalosporin, by Country USD Million (2015-2020)
  • Table 71. Europe Cephalosporin, by Type USD Million (2015-2020)
  • Table 72. Europe Cephalosporin, by Application USD Million (2015-2020)
  • Table 73. Europe Cephalosporin, by Generation USD Million (2015-2020)
  • Table 74. Europe Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 75. Germany Cephalosporin, by Type USD Million (2015-2020)
  • Table 76. Germany Cephalosporin, by Application USD Million (2015-2020)
  • Table 77. Germany Cephalosporin, by Generation USD Million (2015-2020)
  • Table 78. Germany Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 79. France Cephalosporin, by Type USD Million (2015-2020)
  • Table 80. France Cephalosporin, by Application USD Million (2015-2020)
  • Table 81. France Cephalosporin, by Generation USD Million (2015-2020)
  • Table 82. France Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 83. Italy Cephalosporin, by Type USD Million (2015-2020)
  • Table 84. Italy Cephalosporin, by Application USD Million (2015-2020)
  • Table 85. Italy Cephalosporin, by Generation USD Million (2015-2020)
  • Table 86. Italy Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 87. United Kingdom Cephalosporin, by Type USD Million (2015-2020)
  • Table 88. United Kingdom Cephalosporin, by Application USD Million (2015-2020)
  • Table 89. United Kingdom Cephalosporin, by Generation USD Million (2015-2020)
  • Table 90. United Kingdom Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 91. Netherlands Cephalosporin, by Type USD Million (2015-2020)
  • Table 92. Netherlands Cephalosporin, by Application USD Million (2015-2020)
  • Table 93. Netherlands Cephalosporin, by Generation USD Million (2015-2020)
  • Table 94. Netherlands Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 95. Rest of Europe Cephalosporin, by Type USD Million (2015-2020)
  • Table 96. Rest of Europe Cephalosporin, by Application USD Million (2015-2020)
  • Table 97. Rest of Europe Cephalosporin, by Generation USD Million (2015-2020)
  • Table 98. Rest of Europe Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 99. MEA Cephalosporin, by Country USD Million (2015-2020)
  • Table 100. MEA Cephalosporin, by Type USD Million (2015-2020)
  • Table 101. MEA Cephalosporin, by Application USD Million (2015-2020)
  • Table 102. MEA Cephalosporin, by Generation USD Million (2015-2020)
  • Table 103. MEA Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 104. Middle East Cephalosporin, by Type USD Million (2015-2020)
  • Table 105. Middle East Cephalosporin, by Application USD Million (2015-2020)
  • Table 106. Middle East Cephalosporin, by Generation USD Million (2015-2020)
  • Table 107. Middle East Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 108. Africa Cephalosporin, by Type USD Million (2015-2020)
  • Table 109. Africa Cephalosporin, by Application USD Million (2015-2020)
  • Table 110. Africa Cephalosporin, by Generation USD Million (2015-2020)
  • Table 111. Africa Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 112. North America Cephalosporin, by Country USD Million (2015-2020)
  • Table 113. North America Cephalosporin, by Type USD Million (2015-2020)
  • Table 114. North America Cephalosporin, by Application USD Million (2015-2020)
  • Table 115. North America Cephalosporin, by Generation USD Million (2015-2020)
  • Table 116. North America Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 117. United States Cephalosporin, by Type USD Million (2015-2020)
  • Table 118. United States Cephalosporin, by Application USD Million (2015-2020)
  • Table 119. United States Cephalosporin, by Generation USD Million (2015-2020)
  • Table 120. United States Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 121. Canada Cephalosporin, by Type USD Million (2015-2020)
  • Table 122. Canada Cephalosporin, by Application USD Million (2015-2020)
  • Table 123. Canada Cephalosporin, by Generation USD Million (2015-2020)
  • Table 124. Canada Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 125. Mexico Cephalosporin, by Type USD Million (2015-2020)
  • Table 126. Mexico Cephalosporin, by Application USD Million (2015-2020)
  • Table 127. Mexico Cephalosporin, by Generation USD Million (2015-2020)
  • Table 128. Mexico Cephalosporin, by Route of Drug Administration USD Million (2015-2020)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Cephalosporin: by Type(USD Million)
  • Table 140. Cephalosporin Branded , by Region USD Million (2021-2026)
  • Table 141. Cephalosporin Generics , by Region USD Million (2021-2026)
  • Table 142. Cephalosporin: by Application(USD Million)
  • Table 143. Cephalosporin Respiratory Tract Infection , by Region USD Million (2021-2026)
  • Table 144. Cephalosporin Skin Infection , by Region USD Million (2021-2026)
  • Table 145. Cephalosporin Ear Infection , by Region USD Million (2021-2026)
  • Table 146. Cephalosporin Urinary Tract Infection , by Region USD Million (2021-2026)
  • Table 147. Cephalosporin Sexually Transmitted Infection , by Region USD Million (2021-2026)
  • Table 148. Cephalosporin Others , by Region USD Million (2021-2026)
  • Table 149. Cephalosporin: by Generation(USD Million)
  • Table 150. Cephalosporin First-generation Cephalosporin , by Region USD Million (2021-2026)
  • Table 151. Cephalosporin Second-generation Cephalosporin , by Region USD Million (2021-2026)
  • Table 152. Cephalosporin Third-generation Cephalosporin , by Region USD Million (2021-2026)
  • Table 153. Cephalosporin Fourth-generation Cephalosporin , by Region USD Million (2021-2026)
  • Table 154. Cephalosporin Fifth-generation Cephalosporin , by Region USD Million (2021-2026)
  • Table 155. Cephalosporin: by Route of Drug Administration(USD Million)
  • Table 156. Cephalosporin Injection , by Region USD Million (2021-2026)
  • Table 157. Cephalosporin Oral , by Region USD Million (2021-2026)
  • Table 158. South America Cephalosporin, by Country USD Million (2021-2026)
  • Table 159. South America Cephalosporin, by Type USD Million (2021-2026)
  • Table 160. South America Cephalosporin, by Application USD Million (2021-2026)
  • Table 161. South America Cephalosporin, by Generation USD Million (2021-2026)
  • Table 162. South America Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 163. Brazil Cephalosporin, by Type USD Million (2021-2026)
  • Table 164. Brazil Cephalosporin, by Application USD Million (2021-2026)
  • Table 165. Brazil Cephalosporin, by Generation USD Million (2021-2026)
  • Table 166. Brazil Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 167. Argentina Cephalosporin, by Type USD Million (2021-2026)
  • Table 168. Argentina Cephalosporin, by Application USD Million (2021-2026)
  • Table 169. Argentina Cephalosporin, by Generation USD Million (2021-2026)
  • Table 170. Argentina Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 171. Rest of South America Cephalosporin, by Type USD Million (2021-2026)
  • Table 172. Rest of South America Cephalosporin, by Application USD Million (2021-2026)
  • Table 173. Rest of South America Cephalosporin, by Generation USD Million (2021-2026)
  • Table 174. Rest of South America Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 175. Asia Pacific Cephalosporin, by Country USD Million (2021-2026)
  • Table 176. Asia Pacific Cephalosporin, by Type USD Million (2021-2026)
  • Table 177. Asia Pacific Cephalosporin, by Application USD Million (2021-2026)
  • Table 178. Asia Pacific Cephalosporin, by Generation USD Million (2021-2026)
  • Table 179. Asia Pacific Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 180. China Cephalosporin, by Type USD Million (2021-2026)
  • Table 181. China Cephalosporin, by Application USD Million (2021-2026)
  • Table 182. China Cephalosporin, by Generation USD Million (2021-2026)
  • Table 183. China Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 184. Japan Cephalosporin, by Type USD Million (2021-2026)
  • Table 185. Japan Cephalosporin, by Application USD Million (2021-2026)
  • Table 186. Japan Cephalosporin, by Generation USD Million (2021-2026)
  • Table 187. Japan Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 188. India Cephalosporin, by Type USD Million (2021-2026)
  • Table 189. India Cephalosporin, by Application USD Million (2021-2026)
  • Table 190. India Cephalosporin, by Generation USD Million (2021-2026)
  • Table 191. India Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 192. South Korea Cephalosporin, by Type USD Million (2021-2026)
  • Table 193. South Korea Cephalosporin, by Application USD Million (2021-2026)
  • Table 194. South Korea Cephalosporin, by Generation USD Million (2021-2026)
  • Table 195. South Korea Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 196. Taiwan Cephalosporin, by Type USD Million (2021-2026)
  • Table 197. Taiwan Cephalosporin, by Application USD Million (2021-2026)
  • Table 198. Taiwan Cephalosporin, by Generation USD Million (2021-2026)
  • Table 199. Taiwan Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 200. Australia Cephalosporin, by Type USD Million (2021-2026)
  • Table 201. Australia Cephalosporin, by Application USD Million (2021-2026)
  • Table 202. Australia Cephalosporin, by Generation USD Million (2021-2026)
  • Table 203. Australia Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Cephalosporin, by Type USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Cephalosporin, by Application USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Cephalosporin, by Generation USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 208. Europe Cephalosporin, by Country USD Million (2021-2026)
  • Table 209. Europe Cephalosporin, by Type USD Million (2021-2026)
  • Table 210. Europe Cephalosporin, by Application USD Million (2021-2026)
  • Table 211. Europe Cephalosporin, by Generation USD Million (2021-2026)
  • Table 212. Europe Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 213. Germany Cephalosporin, by Type USD Million (2021-2026)
  • Table 214. Germany Cephalosporin, by Application USD Million (2021-2026)
  • Table 215. Germany Cephalosporin, by Generation USD Million (2021-2026)
  • Table 216. Germany Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 217. France Cephalosporin, by Type USD Million (2021-2026)
  • Table 218. France Cephalosporin, by Application USD Million (2021-2026)
  • Table 219. France Cephalosporin, by Generation USD Million (2021-2026)
  • Table 220. France Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 221. Italy Cephalosporin, by Type USD Million (2021-2026)
  • Table 222. Italy Cephalosporin, by Application USD Million (2021-2026)
  • Table 223. Italy Cephalosporin, by Generation USD Million (2021-2026)
  • Table 224. Italy Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 225. United Kingdom Cephalosporin, by Type USD Million (2021-2026)
  • Table 226. United Kingdom Cephalosporin, by Application USD Million (2021-2026)
  • Table 227. United Kingdom Cephalosporin, by Generation USD Million (2021-2026)
  • Table 228. United Kingdom Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 229. Netherlands Cephalosporin, by Type USD Million (2021-2026)
  • Table 230. Netherlands Cephalosporin, by Application USD Million (2021-2026)
  • Table 231. Netherlands Cephalosporin, by Generation USD Million (2021-2026)
  • Table 232. Netherlands Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 233. Rest of Europe Cephalosporin, by Type USD Million (2021-2026)
  • Table 234. Rest of Europe Cephalosporin, by Application USD Million (2021-2026)
  • Table 235. Rest of Europe Cephalosporin, by Generation USD Million (2021-2026)
  • Table 236. Rest of Europe Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 237. MEA Cephalosporin, by Country USD Million (2021-2026)
  • Table 238. MEA Cephalosporin, by Type USD Million (2021-2026)
  • Table 239. MEA Cephalosporin, by Application USD Million (2021-2026)
  • Table 240. MEA Cephalosporin, by Generation USD Million (2021-2026)
  • Table 241. MEA Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 242. Middle East Cephalosporin, by Type USD Million (2021-2026)
  • Table 243. Middle East Cephalosporin, by Application USD Million (2021-2026)
  • Table 244. Middle East Cephalosporin, by Generation USD Million (2021-2026)
  • Table 245. Middle East Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 246. Africa Cephalosporin, by Type USD Million (2021-2026)
  • Table 247. Africa Cephalosporin, by Application USD Million (2021-2026)
  • Table 248. Africa Cephalosporin, by Generation USD Million (2021-2026)
  • Table 249. Africa Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 250. North America Cephalosporin, by Country USD Million (2021-2026)
  • Table 251. North America Cephalosporin, by Type USD Million (2021-2026)
  • Table 252. North America Cephalosporin, by Application USD Million (2021-2026)
  • Table 253. North America Cephalosporin, by Generation USD Million (2021-2026)
  • Table 254. North America Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 255. United States Cephalosporin, by Type USD Million (2021-2026)
  • Table 256. United States Cephalosporin, by Application USD Million (2021-2026)
  • Table 257. United States Cephalosporin, by Generation USD Million (2021-2026)
  • Table 258. United States Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 259. Canada Cephalosporin, by Type USD Million (2021-2026)
  • Table 260. Canada Cephalosporin, by Application USD Million (2021-2026)
  • Table 261. Canada Cephalosporin, by Generation USD Million (2021-2026)
  • Table 262. Canada Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 263. Mexico Cephalosporin, by Type USD Million (2021-2026)
  • Table 264. Mexico Cephalosporin, by Application USD Million (2021-2026)
  • Table 265. Mexico Cephalosporin, by Generation USD Million (2021-2026)
  • Table 266. Mexico Cephalosporin, by Route of Drug Administration USD Million (2021-2026)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cephalosporin: by Type USD Million (2015-2020)
  • Figure 5. Global Cephalosporin: by Application USD Million (2015-2020)
  • Figure 6. Global Cephalosporin: by Generation USD Million (2015-2020)
  • Figure 7. Global Cephalosporin: by Route of Drug Administration USD Million (2015-2020)
  • Figure 8. South America Cephalosporin Share (%), by Country
  • Figure 9. Asia Pacific Cephalosporin Share (%), by Country
  • Figure 10. Europe Cephalosporin Share (%), by Country
  • Figure 11. MEA Cephalosporin Share (%), by Country
  • Figure 12. North America Cephalosporin Share (%), by Country
  • Figure 13. Allergan Plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 14. Allergan Plc. (Ireland) Revenue: by Geography 2020
  • Figure 15. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 16. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 17. F.Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. F.Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 19. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 21. Lupin Limited (Lupin Pharmaceuticals, Inc.) (India) Revenue, Net Income and Gross profit
  • Figure 22. Lupin Limited (Lupin Pharmaceuticals, Inc.) (India) Revenue: by Geography 2020
  • Figure 23. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co. Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 27. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2020
  • Figure 31. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2020
  • Figure 33. Global Cephalosporin: by Type USD Million (2021-2026)
  • Figure 34. Global Cephalosporin: by Application USD Million (2021-2026)
  • Figure 35. Global Cephalosporin: by Generation USD Million (2021-2026)
  • Figure 36. Global Cephalosporin: by Route of Drug Administration USD Million (2021-2026)
  • Figure 37. South America Cephalosporin Share (%), by Country
  • Figure 38. Asia Pacific Cephalosporin Share (%), by Country
  • Figure 39. Europe Cephalosporin Share (%), by Country
  • Figure 40. MEA Cephalosporin Share (%), by Country
  • Figure 41. North America Cephalosporin Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allergan Plc. (Ireland)
  • Bristol-Myers Squibb Company (United States)
  • F.Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Lupin Limited (Lupin Pharmaceuticals, Inc.) (India)
  • Merck & Co. Inc. (United States)
  • Novartis International AG (Switzerland)
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • Teva Pharmaceutical Industries Ltd (Israel)
Additional players considered in the study are as follows:
Eli Lilly and Company (United States) , Bayer HealthCare (Germany) , Sun Pharmaceutical (India) , Shionog (Japan)
Select User Access Type

Key Highlights of Report


Dec 2021 226 Pages 79 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and India Cephalosporin Market Quantitative research analysis
Global and India Cephalosporin Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Cephalosporin study can be customized to meet your requirements. The market size breakdown by type [Branded and Generics], by end use application [Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection and Others].
The Cephalosporin Market is gaining popularity and expected to see strong valuation by 2026.
According to AMA, the Global Cephalosporin market is expected to see growth rate of 2.1%.

Know More About Global and India Cephalosporin Market Report?

Have a Query? Click Here

Other Related Reports

Xylanase Comprehensive Study by Type (Feed grade, Food grade), Application (Feed and livestock, Bleaching of wood pulp, Additive (in poultry), Bakery, Agro waste treatment), End User Industry (Paper ...
$ 3450
Oligonucleotide Pool Library Comprehensive Study by Type (12K Different Oligo per Pools, 90K Different Oligo per Pools, Other), Application (Target Capture, CRISPR/Cas9 Designs, Gene Synthesis, Libra...
$ 3350
Microalgae Comprehensive Study by Type (Spirulina, Chlorella, Arthrospira, Tetraselmis, Others), Application (Food and Feed, Pharmaceuticals, Biofuels), Compounds (Pigments, Fatty acids, Anti-oxidant...
$ 3500
Pectinase Comprehensive Study by Type (Protopectinases, Polygalacturonases, Pectin Lyases, Pectinesterase), End User Industry (Food Industry, Aquaculture Industry, Winemaking Industry, Textile Indust...
$ 3350
Protein Engineering Comprehensive Study by Type (Modified Enzymes, Insulin, Monoclonal Antibodies, Coagulation Factors (Blood factors + Tissue plasminogen), Vaccines, Growth Factors (Hormones + Cytok...
$ 3750
Ginkgo Biloba Extract Comprehensive Study by Type (Tablets, Capsules, Liquid Extracts), Application (Food, Cosmetics, Pharmaceuticals), Distribution Channel (Offline, Online), End Use (Stroke and Oth...
$ 3650